Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis

In addition to dysregulated JAK/STAT signaling, activation of the AKT/mTOR pathway occurs in myelofibrosis, a myeloproliferative neoplasm with no approved therapies. We conducted a phase 1/2 study with everolimus, an mTOR inhibitor, in 39 high- or intermediate-risk primary or postpolycythemia vera/p...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Guglielmelli, Paola, Barosi, Giovanni, Rambaldi, Alessandro, Marchioli, Roberto, Masciulli, Arianna, Tozzi, Lorenzo, Biamonte, Flavia, Bartalucci, Niccolò, Gattoni, Elisabetta, Lupo, Maria Letizia, Finazzi, Guido, Pancrazzi, Alessandro, Antonioli, Elisabetta, Susini, Maria Chiara, Pieri, Lisa, Malevolti, Elisa, Usala, Emilio, Occhini, Ubaldo, Grossi, Alberto, Caglio, Silvia, Paratore, Simona, Bosi, Alberto, Barbui, Tiziano, Vannucchi, Alessandro M.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2011
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3365876/
https://ncbi.nlm.nih.gov/pubmed/21725052
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-01-330563
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky